摘要
目的:探讨新辅助化疗对巨块型ⅠB、ⅡA期宫颈癌的近期疗效和预后影响。方法:回顾性分析了224例新辅助化疗配合腔内后装放疗(治疗组)及100例单独腔内后装放疗(对照组)后再行手术的巨块型ⅠB、ⅡA期宫颈癌的近期疗效和远期疗效。结果:对照组总有效率84.0%,5年生存率60.0%;治疗组总有效率91.1%,5年生存率为68.0%,两组总有效率和5年生存率的差异显著(P<0.05)。治疗组中新辅助化疗的方案对近期疗效无影响(P>0.05)。结论:巨块型ⅠB、ⅡA期宫颈癌术前行新辅助化疗配合腔内后装放射治疗,可能是更好的治疗选择。
Objective:To explore the efficacy of neoadjuvant chemotherapy(NAC) in bulky stage ⅠB and stage ⅡA cervical cancer.Methods:We retrospectively analyzed 224 cases of bulky stage ⅠB and stage ⅡA cervical cancer patients(treatment group) who received NAC and after-loading radiotherapy before operation,and 100 patients(control group) who received after-loading radiotherapy only before operation.Results:NAC combined with after-loading radiotherapy can achieve higher total effective rate(91.1%) and 5-year survival rate(68.0%) than those(84.0%,60.0%) of after-loading radiotherapy only before operation(P〈0.05).The regimen of NAC has no influence on the effective rate in our study(P〉0.05).Conclusion:The bulky stage ⅠB and stage ⅡA cervical cancer patients received NAC and after-loading radiotherapy before operation was an effective selection.
出处
《临床肿瘤学杂志》
CAS
2008年第10期911-913,共3页
Chinese Clinical Oncology
关键词
宫颈癌
新辅助化疗
后装放疗
Cervical cancer
Neoadjuvant chemotherapy(NAC)
After-loading radiotherapy